AU2015221933B2 - APRIL variants - Google Patents

APRIL variants Download PDF

Info

Publication number
AU2015221933B2
AU2015221933B2 AU2015221933A AU2015221933A AU2015221933B2 AU 2015221933 B2 AU2015221933 B2 AU 2015221933B2 AU 2015221933 A AU2015221933 A AU 2015221933A AU 2015221933 A AU2015221933 A AU 2015221933A AU 2015221933 B2 AU2015221933 B2 AU 2015221933B2
Authority
AU
Australia
Prior art keywords
april
bcma
seq
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015221933A
Other languages
English (en)
Other versions
AU2015221933A1 (en
Inventor
Neil CHAPLIN
Ben DRAPER
Lydia LEE
Martin Pule
Kwee YONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201403479A external-priority patent/GB201403479D0/en
Priority claimed from GB201403481A external-priority patent/GB201403481D0/en
Priority claimed from GB201409759A external-priority patent/GB201409759D0/en
Priority claimed from GB201409761A external-priority patent/GB201409761D0/en
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of AU2015221933A1 publication Critical patent/AU2015221933A1/en
Application granted granted Critical
Publication of AU2015221933B2 publication Critical patent/AU2015221933B2/en
Assigned to UCL BUSINESS LTD reassignment UCL BUSINESS LTD Amend patent request/document other than specification (104) Assignors: UCL BUSINESS PLC
Assigned to Autolus Limited reassignment Autolus Limited Request for Assignment Assignors: UCL BUSINESS LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
AU2015221933A 2014-02-27 2015-02-26 APRIL variants Ceased AU2015221933B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1403481.3 2014-02-27
GB201403479A GB201403479D0 (en) 2014-02-27 2014-02-27 Molecule
GB201403481A GB201403481D0 (en) 2014-02-27 2014-02-27 Chimeric antigen receptor
GB1403479.7 2014-02-27
GB1409761.2 2014-06-02
GB1409759.6 2014-06-02
GB201409759A GB201409759D0 (en) 2014-06-02 2014-06-02 Molecule
GB201409761A GB201409761D0 (en) 2014-06-02 2014-06-02 Chimeric antigen receptor
PCT/GB2015/050557 WO2015128653A2 (en) 2014-02-27 2015-02-26 Ligand

Publications (2)

Publication Number Publication Date
AU2015221933A1 AU2015221933A1 (en) 2016-09-01
AU2015221933B2 true AU2015221933B2 (en) 2019-09-12

Family

ID=52633311

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015221933A Ceased AU2015221933B2 (en) 2014-02-27 2015-02-26 APRIL variants

Country Status (8)

Country Link
US (2) US10752665B2 (enExample)
EP (2) EP3110838B1 (enExample)
JP (3) JP6556156B2 (enExample)
CN (1) CN106414502A (enExample)
AU (1) AU2015221933B2 (enExample)
CA (1) CA2939411A1 (enExample)
ES (1) ES2737690T3 (enExample)
WO (1) WO2015128653A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
AU2015221933B2 (en) 2014-02-27 2019-09-12 Autolus Limited APRIL variants
US11253546B2 (en) 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
KR102528825B1 (ko) 2015-04-13 2023-05-08 화이자 인코포레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
CN109641012A (zh) * 2016-06-07 2019-04-16 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 与bcma结合的嵌合抗原受体和car-t细胞
WO2018042385A2 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
CN108277205B (zh) * 2016-12-30 2022-12-20 四川大学 表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途
JP2021500882A (ja) * 2017-10-18 2021-01-14 プレシゲン，インコーポレイテッド スペーサーを含むポリペプチド組成物
EP3704157A1 (en) 2017-11-01 2020-09-09 Hummingbird Bioscience Holdings Pte. Ltd. Cd47 antigen-binding molecules
GB201720426D0 (en) * 2017-12-07 2018-01-24 Hummingbird Bioscience Pte Ltd CD47 and BCMA antigen-binding molecules
JP7566628B2 (ja) * 2018-01-10 2024-10-15 ザ ジェネラル ホスピタル コーポレイション キメラ抗原受容体を発現する免疫細胞
CN112533942A (zh) 2018-06-01 2021-03-19 华盛顿大学 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制
CN112566643A (zh) * 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
CN114206919B (zh) * 2019-06-04 2025-07-15 综合医院公司 靶向taci的抗体和嵌合抗原受体
CN110642953B (zh) * 2019-10-12 2021-09-17 华夏源（上海）细胞基因工程股份有限公司 一种靶向bcma的t细胞受体融合蛋白和应用
CA3227108A1 (en) 2021-08-11 2023-02-16 Xiaomeng HU Genetically modified primary cells for allogeneic cell therapy
US20250127820A1 (en) 2021-08-11 2025-04-24 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
EP4384544A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
JP2024534771A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2024097315A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Cell therapy products and methods for producing same
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020593A2 (en) * 2002-08-30 2004-03-11 Incyte Corporation Immune response associated proteins
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
AU2048501A (en) * 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050003480A1 (en) * 2003-01-06 2005-01-06 Xencor April variants and methods thereof
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
HK1203393A1 (en) 2012-04-11 2015-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
AU2015221933B2 (en) 2014-02-27 2019-09-12 Autolus Limited APRIL variants
CN110114371A (zh) 2016-11-11 2019-08-09 奥托路斯有限公司 嵌合抗原受体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020593A2 (en) * 2002-08-30 2004-03-11 Incyte Corporation Immune response associated proteins
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"PREDICTED: tumor necrosis factor ligand superfamily member 13-like isoform X1 [Echinops telfairi]", UniParc, (2013-05-30), Database accession no. UPI000333ABF8, URL: EBI *
"PREDICTED: tumor necrosis factor ligand superfamily member 13-like isoform X2 [Echinops telfairi]", UniParc, (2013-05-30), Database accession no. UPI000333A0DD, URL: EBI *
"SubName: Full=Tumor necrosis factor ligand superfamily member 13 {ECO:0000313Ensembl:ENSP00000410094}; Flags: Fragment;", UniProt, (2009-11-03), Database accession no. C9JF68, URL: EBI *
F. C. KIMBERLEY ET AL, "The Design and Characterization of Receptor-selective APRIL Variants", JOURNAL OF BIOLOGICAL CHEMISTRY, (2012-10-26), vol. 287, no. 44, doi:10.1074/jbc.M112.406090, ISSN 0021-9258, pages 37434 - 37446 *

Also Published As

Publication number Publication date
EP3110838A2 (en) 2017-01-04
JP2017145258A (ja) 2017-08-24
AU2015221933A1 (en) 2016-09-01
CN106414502A (zh) 2017-02-15
ES2737690T3 (es) 2020-01-15
US20160362467A1 (en) 2016-12-15
WO2015128653A2 (en) 2015-09-03
JP6707496B2 (ja) 2020-06-10
EP3243831A1 (en) 2017-11-15
EP3110838B1 (en) 2019-06-26
JP2019068855A (ja) 2019-05-09
US10752665B2 (en) 2020-08-25
JP2017514787A (ja) 2017-06-08
JP6556156B2 (ja) 2019-08-07
US20170334964A1 (en) 2017-11-23
CA2939411A1 (en) 2015-09-03
US10611811B2 (en) 2020-04-07
WO2015128653A3 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
AU2015221933B2 (en) APRIL variants
US20240076352A1 (en) Chimeric Antigen Receptor
US11492408B2 (en) Bi-specific T-cell engager specific for BCMA
BR112019017629A2 (pt) receptor de união ao antígeno, polinucleotídeo isolado, vetor, célula t transduzida, métodos para o tratamento de uma doença e para induzir a lise, utilização do receptor e receptor
CN111479918A (zh) 细胞
WO2022093694A1 (en) Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof
KR20220122844A (ko) Cd22에 특이적인 인간화 항체 및 이의 용도
JP2025512797A (ja) 改善されたキメラ受容体
HK1227893A1 (en) April variants
HK1227893B (en) April variants
KR102548256B1 (ko) Cd22에 특이적인 항체 및 이의 용도
KR20220155943A (ko) Cd22에 특이적인 항체 및 이의 용도
CN121057751A (zh) 结合nkp80的nk细胞接合剂及其用途
HK1222186B (en) Chimeric antigen receptor

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UCL BUSINESS LTD

Free format text: FORMER NAME(S): UCL BUSINESS PLC

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: AUTOLUS LIMITED

Free format text: FORMER OWNER(S): UCL BUSINESS LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired